The U.S. Food and Drug Administration (FDA) has approved Yescarta, a Car-T cell therapy, for lymphoma patients.
Developed by Kite Pharma and Gilead Sciences, a Leukemia Research Foundation sponsor, the therapy involves removing a patient's own immune T-cells, reengineering them to recognize and fight the cancer, then infusing them back into the patient. This is the second Car-T cell therapy approved by the FDA. The first was approved in August.
Learn more about this exciting advancement for lymphoma patients by clicking here.